The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
June 12, 2023
Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
June 12, 2023 (Issue: 1678)
Asciminib (Scemblix – Novartis), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with Philadelphia chromosome-positive
chronic myeloid leukemia (Ph+ CML) in chronic
phase (CP) previously treated with ≥2 tyrosine...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.